Trial Profile
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ragweed allergy immunotherapy (Primary) ; Monophosphoryl lipid A
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Pharmacodynamics
- 27 Oct 2009 New trial record